Explore our latest research-grade biosimilar antibodies for therapeutic target validation and drug discovery
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Understanding the structural and functional advantages of VHH single-domain antibodies in modern drug discovery
VHH antibodies (nanobodies) are derived from the variable domain of heavy-chain-only antibodies found in camelids. Their compact ~15 kDa single-domain structure enables access to cryptic epitopes inaccessible to conventional antibodies, making them ideal for targeting GPCRs, ion channels, and enzyme active sites.
Nanobodies exhibit exceptional thermal and chemical stability, high solubility, and low immunogenicity after humanization. Their small size facilitates rapid tissue penetration and efficient renal clearance, enabling flexible pharmacokinetic tuning for diverse therapeutic indications.
VHH domains can be seamlessly fused into bispecific constructs, CAR-T cell receptors, antibody-drug conjugates (ADCs), and intrabodies. Their prokaryotic expression compatibility drastically reduces manufacturing costs compared to conventional IgG biologics.
The global nanobody therapeutics market is experiencing explosive growth, driven by the clinical validation of Caplacizumab (the first approved nanobody drug) and an expanding pipeline of over 50 VHH-based candidates in clinical trials across oncology, autoimmune, and infectious disease indications.
Major pharmaceutical companies including Sanofi, AbbVie, and Novo Nordisk have invested heavily in VHH platforms through strategic acquisitions and partnerships. The market is projected to exceed USD 9.2 billion by 2030, with a CAGR of 26.4%, fueled by next-generation bispecific nanobodies and VHH-based radiopharmaceuticals.
AI-powered antibody discovery is reshaping the competitive landscape. Deep learning models now accelerate VHH library design, epitope prediction, and affinity maturation — compressing discovery timelines from years to months. Alpha Lifetech integrates these computational tools with its wet-lab platforms to deliver unmatched speed-to-candidate performance.
How VHH antibody platforms are transforming drug discovery across multiple disease areas
VHH-based bispecific T-cell engagers and CAR-T constructs are redefining cancer immunotherapy. Their ability to simultaneously engage tumor antigens and immune effectors — with superior tumor penetration compared to full-length IgG — positions nanobodies as ideal building blocks for next-generation oncology biologics.
The compact size of VHH antibodies enables unprecedented blood-brain barrier (BBB) transcytosis efficiency. Nanobodies targeting transferrin receptor (TfR) have demonstrated 10-fold greater brain uptake than conventional antibodies, opening new therapeutic windows for Alzheimer's, Parkinson's, and glioblastoma.
VHH-ADC platforms leverage the precise tumor-targeting of nanobodies with the cytotoxic payload delivery of small molecules. Their uniform conjugation chemistry and rapid tumor internalization result in superior therapeutic indices compared to conventional IgG-ADCs, with reduced off-target toxicity.
Multivalent VHH constructs targeting conserved viral epitopes offer broad-spectrum neutralization against SARS-CoV-2 variants, influenza, and RSV. Their inhaled delivery format — enabled by aerosolization stability — represents a paradigm shift in respiratory virus prophylaxis and treatment.
The rapid tumor uptake and fast blood clearance of VHH antibodies create ideal pharmacokinetic profiles for PET/SPECT imaging agents. VHH-based radiopharmaceuticals are advancing through clinical trials as companion diagnostics and theranostic agents for precision oncology.
Unlike conventional antibodies, VHH domains can fold correctly in the reducing environment of the cytoplasm, enabling intrabody applications that modulate intracellular protein-protein interactions — a previously undruggable target class representing over 60% of the human proteome.
Alpha Lifetech's integrated VHH discovery ecosystem combines AI-driven library design, high-throughput phage/yeast display screening, single-B cell sorting, and advanced biophysical characterization — delivering validated therapeutic nanobody leads in as little as 12 weeks. Our end-to-end platform supports discovery through IND-enabling studies, with GMP-compatible processes for seamless clinical translation.
Through tailored products, adaptable service and packaging choices, and unwavering support, Alpha Lifetech Inc. guarantees that researchers have access to the most fitting and efficient tools tailored to their research endeavors.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian.
Our Membrane Proteomics platform offers a comprehensive solution for the identification, quantification, and characterization of membrane proteins, providing valuable insights into their functions and interactions within the cell.
Alpha Lifetech can offer the native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Goat, Camel and Llama.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies. This multi-format capability allows our clients to select the optimal antibody architecture for their specific therapeutic modality — whether pursuing checkpoint inhibitors, receptor agonists, or enzyme inhibitors.
The VHH discovery workflow integrates camelid immunization, immune library construction, high-throughput phage display panning, ELISA screening, and comprehensive biophysical characterization including SPR and BLI kinetic analysis — delivering fully characterized lead candidates ready for humanization and downstream development.
READ MORE
VHH Antibody Discovery Service
View Details
Fab Antibody Discovery Service
View Details
ScFv Antibody Discovery Service
View Details
Phage Display System
View Details
Phage Library Construction Service
View DetailsThe aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
Complementing our VHH antibody discovery capabilities, aptamer-based targeting agents offer chemical synthesis scalability and flexible modification chemistries — enabling novel bispecific conjugates that combine the specificity of nanobodies with the manufacturing advantages of oligonucleotide therapeutics.
READ MORE
Aptamer Synthesis Platform
View Details
Aptamer Screening Platform
View Details
Aptamer Optimization Service
View Details
Aptamer Analysis Service
View Details
Aptamer Research Service
View Details
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species. This multi-platform approach ensures optimal antibody generation regardless of target complexity, immunogenicity, or desired species specificity.
Alpha Lifetech Inc. provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, and hybridoma technology. Whether you're engaged in immunology, cell biology, molecular biology, or any other scientific discipline, our comprehensive suite of services is designed to empower you with precise and dependable results.
READ MORE
Single B Cell Sorting Platform
View Details
Hybridoma Technology Platform
View Details
Phage Display Technology Platform
View Details
Mouse mAb Development Service
View Details
Rabbit mAb Development Service
View DetailsWe also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development. These enabling technologies are critical for validating therapeutic candidates, optimizing binding kinetics, and establishing scalable production systems required for IND-enabling studies.
Our protein interaction analysis capabilities — including SPR (Surface Plasmon Resonance) and BLI (Bio-Layer Interferometry) — provide real-time, label-free kinetic characterization of VHH-target interactions, delivering the precise KD, kon, and koff data required for lead selection and optimization in therapeutic programs.
READ MORE
Stable Cell Line Construction Service
View Details
Animal Immunization Platform
View Details
Protein Interaction Service
View Details
Yeast Display Library Construction Service
View Details
Yeast Display Library Screening Service
View Details
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Our years of manufacturing experience and refined products provide you with better protection
Exceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
Quality products! Our experience with Alpha Lifetech has been nothing short of outstanding. Simply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner.
Reliable, responsive, and results-driven — Alpha Lifetech. Their VHH discovery platform exceeded our expectations in both throughput and lead quality. We successfully identified high-affinity nanobodies against a challenging membrane protein target within the agreed timeline.
Comprehensive research-grade biosimilar antibodies supporting therapeutic target validation across oncology, immunology, and beyond
Partner with Alpha Lifetech's VHH Antibody Discovery Platform to unlock the full potential of nanobody therapeutics. From target engagement to IND-enabling studies, our integrated platform delivers validated leads with speed, precision, and scientific excellence.
Start Your VHH Discovery Project